Dr. Claudio Vernieri shares key insights from his ESMO 2025 poster exploring the real-world effectiveness of first-line endocrine therapy combined with CDK4/6 inhibitors in HR+/HER2- advanced breast cancer, focusing on treatment outcomes and clinical implications.
